CorMatrix Receives FDA IDE Approval To Begin Prospective, Randomized Evaluation Of New Onset Postoperative Atrial Fibrillation
Links shared publicly online about this topic.
- 881total visits
CorMatrix Receives FDA IDE Approval To Begin Prospective, Randomized Evaluation Of New Onset Postoperative Atrial Fibrillation
CorMatrix Cardiovascular, Inc., a medical device company developing and delivering unique extracellular matrix (ECM) biomaterial devices that harness the body's innate ability to repair damaged ca
View full resource at medicalnewstoday.com
Tags: Heart Disease, Arrhythmia, Atrial Fibrillation, Medical Device, FDA
Most Recently Shared on September 11, 2010 at 4:00 pm By:
CorMatrix Receives FDA IDE Approval To Begin Prospective, Randomized Evaluation Of New Onset Postoperative Atrial Fibr... http://mnt.to/3JCp
Also Shared By:
Advertisement
Heart Health
@HeartsHealth
MedicalNewsToday: CorMatrix Receives FDA IDE Approval To Begin Prospective, Randomized: http://bit.ly/95HaWc Full http://bit.ly/bnCBL8
1 year ago...